Track your holdings and dividends manually for free. Subscribe to link your brokerage through Plaid and automatically sync holdings and dividend payments.
Data last updated: Nov 18, 2026
Snapshot (as of Nov 18, 2026): Bayer Aktiengesellschaft (BAYRY) pays a $0.11 annual dividend, yielding 0.21% at $15.43/share. Next ex-dividend date 2026-04-28. Source: Yahoo Finance, aggregated by MerryDiv.
Dividend Yield: 0.21%
Annual Dividend: $0.11 per share
Payout Ratio: 171.3% (based on depressed trailing earnings — see safety analysis below)
Ex-Dividend Date: 2026-04-28
Dividend Frequency: annually
Sector: Healthcare
Years of Dividend History: 32
Bayer Aktiengesellschaft dividend investors are working with a yield of just 0.25% from a company spanning pharmaceuticals, consumer health, and crop science across more than 90 countries. The trailing annual dividend rate based on actual TTM payments is $0.11 per share, paid annually, with the next ex-dividend date on April 28, 2026. BAYRY operates across prescription cardiology drugs, over-the-counter consumer products, and agricultural crop protection, giving it broad revenue exposure across three distinct life science segments. With a beta of 0.839, the stock moves less than the broader market, which appeals to investors who prioritize lower volatility over high income.
Bayer Aktiengesellschaft pays out 171.3% of earnings as dividends, a payout ratio classified as high (above 75%). That figure means the company is paying out more in dividends than it earns, which raises real questions about Bayer Aktiengesellschaft dividend safety regardless of the breadth of its pharmaceutical, consumer health, and crop science businesses. The most significant data-supported pressure point is the payout ratio itself: at 171.3%, there is no earnings cushion, and any further earnings deterioration would put the current $0.03 annual forward rate under direct strain.
Bayer Aktiengesellschaft dividend history shows a CAGR of -15.3% per year from 2008 to 2025. The per-share dividend fell from $0.5241 at the start of the window to $0.0311 by 2025 (with 2026 partial at $0.0321). The largest annual increase in the window was 66.3% in 2018, but that spike was followed by sharp declines, and the overall trajectory across 17 years is one of severe erosion, not growth.
| Period | CAGR | From | To |
|---|---|---|---|
| 10-Year | -25.8% | $0.62 (2015) | $0.03 (2025) |
BAYRY is a low-yield, high-payout stock with a dividend that has shrunk dramatically over time, making it a poor fit for income-focused investors who prioritize growing or even flat payouts. The current yield of 0.25% sits well below its 5-year average of 0.64%, a low (below 2%) figure by any income standard. The 171.3% payout ratio means the dividend is not covered by earnings at current levels. What an investor gets here is exposure to a diversified life science business spanning drugs, consumer health, and agriculture, but the trade-off is a dividend that has declined at -15.3% per year over 17 years and offers minimal income today.
| Payment Date | Amount per Share |
|---|---|
| 2026-04-28 | $0.0321 |
| 2025-04-29 | $0.0311 |
| 2024-04-29 | $0.0294 |
| 2023-05-02 | $0.6602 |
| 2022-05-02 | $0.5258 |
| 2021-04-28 | $0.6041 |
| 2020-04-29 | $0.7626 |
| 2019-04-29 | $0.7823 |
| 2018-06-22 | $0.4162 |
| 2018-05-25 | $0.8131 |
| Year | Total Dividends |
|---|---|
| 2026 | $0.0321 |
| 2025 | $0.0311 |
| 2024 | $0.0294 |
| 2023 | $0.6602 |
| 2022 | $0.5258 |
Project income from BAYRY with the BAYRY dividend calculator or track your full portfolio with the dividend tracker.